Document Detail


Cardiovascular effects of tadalafil in patients on common antihypertensive therapies.
MedLine Citation:
PMID:  14609623     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Tadalafil is a potent, selective, reversible phosphodiesterase 5 inhibitor under investigation for the treatment of erectile dysfunction (ED). Because some oral agents for ED have vasodilator properties, interaction studies were performed between tadalafil and commonly prescribed antihypertensive agents. In addition, cardiovascular safety assessments were made from a safety database of phase 3 studies comparing patients who were and who were not receiving antihypertensives. In patients receiving concomitant antihypertensive therapy, tadalafil administration may result in a reduction in blood pressure, which is, in general, mild and not likely to be of clinical concern. In the phase 3 studies, no statistically significant differences were observed between tadalafil and placebo in the mean changes in blood pressure from baseline in patients taking >or=2 antihypertensive agents. The incidence rates of cardiovascular events were comparable between patients who were and were not treated with concomitant antihypertensive therapy, with the exception of events recorded as hypertension, which would be expected to occur periodically in this patient population despite treatment. Hypotension or postural hypotension was not reported in any tadalafil-treated patient, compared with 1 report of each in the placebo-treated patients. Syncope was reported in 1 tadalafil-treated patient (0.1%) who was not on concomitant antihypertensive medication and in 2 patients (1.9%) who received placebo with concomitant antihypertensive agents. The data presented herein suggest that tadalafil is safe in patients receiving >or=1 concomitant antihypertensive agent.
Authors:
Robert A Kloner; Malcolm Mitchell; Jeffrey T Emmick
Related Documents :
19762403 - Pulmonary hypertension in polymyositis-dermatomyositis: clinical and hemodynamic charac...
3662703 - Predisposing factors for the development of malignant essential hypertension.
21069463 - Exacerbation of erythropoietic protoporphyria by hyperthyroidism.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  The American journal of cardiology     Volume:  92     ISSN:  0002-9149     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  2003 Nov 
Date Detail:
Created Date:  2003-11-11     Completed Date:  2003-12-16     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  47M-57M     Citation Subset:  AIM; IM    
Affiliation:
Division of Cardiovascular Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, California, USA. rkloner@goodsam.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
3',5'-Cyclic-GMP Phosphodiesterases / antagonists & inhibitors*
Antihypertensive Agents / pharmacology*
Carbolines / pharmacology*
Cardiovascular System / drug effects*
Clinical Trials as Topic
Drug Interactions
Erectile Dysfunction / drug therapy*
Hemodynamics / drug effects
Humans
Hypertension / drug therapy*
Male
Phosphodiesterase Inhibitors / pharmacology*
Chemical
Reg. No./Substance:
0/Antihypertensive Agents; 0/Carbolines; 0/Phosphodiesterase Inhibitors; 0/tadalafil; EC 3.1.4.35/3',5'-Cyclic-GMP Phosphodiesterases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Cardiovascular effects of tadalafil.
Next Document:  Replication and expression of a swinepox virus vector delivering feline leukemia virus Gag and Env t...